Category: Markets
Published: 2026-07-16T13:00:00.000Z
Arcutis Biotherapeutics announced the appointment of Christopher Peetz, CEO of Mirum Pharmaceuticals, to its Board of Directors effective July 15, 2026. Peetz brings extensive biopharmaceutical leadership experience from roles at multiple companies including Onyx Pharmaceuticals and Tobira. The appointment comes as Arcutis continues to expand its ZORYVE (roflumilast) franchise for treating inflammatory skin diseases and evaluates pipeline expansion through strategic acquisitions.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.